Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo David S. Baldwin, Satoshi Asakura, Tsukasa Koyama,

Slides:

Advertisements

Similar presentations

European Neuropsychopharmacology

Advertisements

OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: A randomized, placebo-controlled cross-over study Tannetje.

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Bipolar treatment efficacy

Volume 119, Issue 10, Pages (October 2012)

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Karen Maguiness, Gavin.

Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta- analysis of randomized clinical trials Yue Han, MD, Yuxin Chen,

Aggressive Behavior in Patients With Stroke: Association With Psychopathology and Results of Antidepressant Treatment on Aggression Keen-Loong Chan,

L. Boyanova Clinical Microbiology and Infection

Volume 10, Issue 7, Pages (July 2018)

Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure Stephen J.D. O'Keefe, Palle B. Jeppesen,

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower- Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005.

Volume 135, Issue 4, Pages (October 2008)

Approach to diagnosis of infective endocarditis

The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis Emmilia A. Dowlatshahi,

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure Stephen J.D. O'Keefe, Palle B. Jeppesen,

Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter,

Adult bacterial meningitis—a quality registry study: earlier treatment and favourable outcome if initial management by infectious diseases physicians

David J. Brenner, Eric J. Hall, Rochelle E. Curtis, Elaine Ron

Use of the Cumulative Proportion of Responders Analysis Graph to Present Pain Data Over a Range of Cut-Off Points: Making Clinical Trial Data More Understandable

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

George E. Kikano, MD, Marie T. Brown, MD Mayo Clinic Proceedings

Once-Daily Gastroretentive Gabapentin for Postherpetic Neuralgia: Integrated Efficacy, Time to Onset of Pain Relief and Safety Analyses of Data From Two.

Proportion of Patients Achieving a ≥30% Reduction in Pain Scores at Week 12 of Stable Dose Treatment

Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double- blind, placebo-controlled trials Stephen B Hanauer, Ulf Strömberg

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Incident diabetes in clinical trials of antihypertensive drugs

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis P.C. Minneci, K.J. Deans, P.Q. Eichacker, C. Natanson

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Rotavirus vaccination: a concise review

Severe Constipation Clinical Gastroenterology and Hepatology

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Karen Maguiness, Gavin.

Efficacy and Safety of a Magnesium Sulfate–Rich Natural Mineral Water for Patients With Functional Constipation Christophe Dupont, Alain Campagne, Florence.

Issue Highlights Clinical Gastroenterology and Hepatology

J. Ranstam Osteoarthritis and Cartilage

Acute pain: combination treatments and how we measure their efficacy

Histologic Changes in Liver Tissue From Patients With Chronic Hepatitis B and Minimal Increases in Levels of Alanine Aminotransferase: A Meta-analysis.

Early decreases in blood eosinophil levels with reslizumab

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

Low-technology approaches

Volume 61, Issue 4, Pages (April 2002)

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci H.L. DuPont, Z.-D. Jiang Clinical Microbiology.

Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis Chloé Théréné, Emilie Brenaut, Thomas Barnetche,

Comparing two low-energy diets for the treatment of knee osteoarthritis symptoms in obese patients: a pragmatic randomized clinical trial B.F. Riecke,

Low-dose SoluMatrix meloxicam results in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis R. Altman, M.

Effect of Folic Acid, with or without Other B Vitamins, on Cognitive Decline: Meta- Analysis of Randomized Trials David S. Wald, MA, MRCP, MD, Anuradhani.

Sanford Chodosh Clinical Microbiology and Infection

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Depression and state anxiety scores during assisted reproductive treatment are associated with outcome: a meta-analysis Satvinder Purewal, Sarah C.E.

Issue Highlights Clinical Gastroenterology and Hepatology

Evaluation of diagnostic tests

Volume 67, Issue 3, Pages (March 2005)

News & Notes Journal of Allergy and Clinical Immunology

Medical Treatment of Overactive Bladder: In Response

Volume 79, Issue 5, Pages (March 2011)

Issue Highlights Clinical Gastroenterology and Hepatology

Preoperative Smoking Cessation: The Role of the Primary Care Provider

Nicholas Z. Kerin, MD, Sony Jacob, MD The American Journal of Medicine

The Editors' Choice Journal of Allergy and Clinical Immunology

Volume 121, Issue 4, Pages (October 2001)

Volume 59, Issue 5, Pages (May 2001)

Scott K. Fung, Anna S.F. Lok Clinical Gastroenterology and Hepatology

The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection∗

Treatment versus Transplant for Challenging Hematologic Disorders

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

The play of chance Fertility and Sterility

Volume 2, Issue 6, Pages (June 2017)

Presentation transcript:

Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo David S. Baldwin, Satoshi Asakura, Tsukasa Koyama, Taiji Hayano, Atsushi Hagino, Elin Reines, Klaus Larsen European Neuropsychopharmacology Volume 26, Issue 6, Pages 1062-1069 (June 2016) DOI: 10.1016/j.euroneuro.2016.02.013 Copyright © 2016 Terms and Conditions

Figure 1 Estimated treatment difference in the Liebowitz Social Anxiety Scale (LSAS) total score at Week 12 (primary analysis) for all 3 studies shown with 95% confidence intervals. All of the tests for heterogeneity within dose are non-significant (p>0.05), so the analysis is based on a fixed effects model. Negative values are in favour of escitalopram, while positive values are in favour of placebo. Patient numbers are shown for escitalopram (Esc) and placebo (Pbo). European Neuropsychopharmacology 2016 26, 1062-1069DOI: (10.1016/j.euroneuro.2016.02.013) Copyright © 2016 Terms and Conditions

Figure 2 Estimated treatment difference in the Clinical Global Impression-Severity (CGI-S) total score at Week 12 for all 3 studies shown with 95% confidence intervals. All of the tests for heterogeneity within dose are non-significant (p>0.05), so the analysis is based on a fixed effects model. Negative values are in favour of escitalopram, while positive values are in favour of placebo. Patient numbers are shown for escitalopram (Esc) and placebo (Pbo). European Neuropsychopharmacology 2016 26, 1062-1069DOI: (10.1016/j.euroneuro.2016.02.013) Copyright © 2016 Terms and Conditions

Figure 3 Estimated treatment difference in the proportion of patients responding to treatment at Week 12 for all 3 studies, based on a Clinical Global Impression-Improvement (CGI-I) of 1 or 2 (with 95% confidence intervals). The number-needed-to-treat (NNT) is the inverse of the difference between escitalopram and placebo in the proportion of patients responding to treatment, rounded up to the nearest integer. European Neuropsychopharmacology 2016 26, 1062-1069DOI: (10.1016/j.euroneuro.2016.02.013) Copyright © 2016 Terms and Conditions